Riskpilot← Back to searchSign inGet full accessNeumirna Therapeutics ApS
APSActiveCVR 41696451A.C. Meyers Vænge 15Research and experimental development on natural sciences and engineering · NACE 7210Est. 202012 employees
Revenue 2024
DKK -5,5M
0% vs 2023
EBITDA margin
150.8%
-9% vs 2023
Equity ratio
-334.5%
Financial strength
Net profit 2024
DKK -7M
+13% vs 2023
| Revenue | DKK -5,5M | +0% |
| EBITDA | DKK -8,3M | -9% |
| Net profit | DKK -7M | +13% |
| Total assets | DKK 5,5M | -12% |
| Equity | DKK -18,4M | -61% |
| Employees | 12 | — |
Legal name
Neumirna Therapeutics ApS
CVR number
41696451
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
21. september 2020
Share capital
DKK 193.816
Employees
12 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør i forening med bestyrelsesformanden eller af den samlede bestyrelse.
Company purpose
Selskabets formål er forskning, udvikling og kommercialisering af lægemidler.
Address
A.C. Meyers Vænge 15
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | -5.781 | -4.661 | -5.476 | -5.496 |
| Staff expenses | -1.420 | -1.701 | -2.154 | -2.794 |
| EBITDA | -7.201 | -6.361 | -7.630 | -8.290 |
| Depreciation & amort. | -0 | -0 | -0 | -0 |
| EBIT | -7.201 | -6.361 | -7.630 | -8.290 |
| Net financials | -414 | -419 | -2.114 | -428 |
| Profit before tax | -7.615 | -6.780 | -9.745 | -8.719 |
| Tax | -1.547 | -1.488 | -1.710 | -1.765 |
| Net profit | -6.068 | -5.292 | -8.034 | -6.954 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 5.746 | 8.972 | 6.255 | 5.507 |
| Equity | 1.859 | -3.434 | -11.468 | -18.422 |
| Long-term debt | 3.318 | 11.081 | 16.840 | 156 |
| Short-term debt | 569 | 1.324 | 883 | 23.773 |
| Total debt | 3.887 | 12.406 | 17.723 | 23.929 |
EBITDA margin
-829035200.0%
This company
15.8%
Market median
-5247058328% vs market
20212024
Equity ratio
-334.5%
This company
38.2%
Market median
-976% vs market
20212024
Return on equity
-695420100.0%
This company
18.4%
Market median
-3779457165% vs market
20212024
Net profit margin
-695420100.0%
This company
8.1%
Market median
-8585433433% vs market
20212024
Asset turnover
-1.00×
This company
1.12×
Market median
-189% vs market
20212024
Debt / equity
1.30×
This company
0.62×
Market median
-110% vs market
20212024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2020-09-21 – 2021-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JT Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
EK Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2021 | — | — | |
| Chairman | 2025 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2025 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2026 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
HELLERUNG ApS | Company | 25.0% | 25.0% | 2025 |
| Individual | 15.0% | 15.0% | 2025 | |
| Individual | 15.0% | 15.0% | 2025 | |
| Individual | 10.0% | 10.0% | 2025 | |
| Individual | 5.0% | 5.0% | 2020 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
HELLERUNG ApS
Neumirna Therapeutics ApS Board members of Neumirna Therapeutics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Janine Terra Erler | Chief Executive Officer | 0 companies |
| Ellen Kinson Donnelly | Chief Executive Officer | 0 companies |
| Markus Sakari Kauppinen | Board of Directors | 0 companies |
| Milla Koistinaho | Board of Directors | 0 companies |
| Mads Spangaard Rasmussen | Chairman | 0 companies |
| Luis Garcia Pareras | Chairman | 0 companies |
| Henrik Valdemar Klitgaard | Board of Directors | 0 companies |
| Morten Priskorn | Board of Directors | 0 companies |
| Andreas Wallnöfer | Board of Directors | 0 companies |
| Sten Verland | Chairman | 0 companies |
| Francesco Paolo Di Giorgio | Board of Directors | 0 companies |
| Lars Hellerung Christiansen | Chairman | 0 companies |
| Thomas Michael Thestrup | Board of Directors | 0 companies |